Zobrazeno 1 - 10
of 17
pro vyhledávání: '"M. E. Guseva"'
Autor:
S. A. Sivertseva, K. S. Anfilofeva, A. V. Zotova, V. D. Chukreev, A. Yu. Belkina, L. I. Volkova, M. E. Guseva, A. N. Boyko
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 16, Iss 0, Pp 18-24 (2024)
Multiple sclerosis (MS) is a chronic autoimmune disease of the nervous system of a predominantly progressive nature. In addition to diseasemodifying drug therapy of MS patients require physical rehabilitation, including tele-rehabilitation (TeleRBT).
Externí odkaz:
https://doaj.org/article/4ef33963855e40a2929516f0f8aa3bbe
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 13, Iss 1S, Pp 45-49 (2021)
Objective: to study the effectiveness of art therapy methods in the complex treatment of neuropsychological disorders and quality of life improvement in patients with relapsing-remitting and secondary-progressive multiple sclerosis (MS).Patients and
Externí odkaz:
https://doaj.org/article/39227b8893f3462da036486104d8c329
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 10, Iss 1, Pp 70-73 (2018)
The review presents the data characterizing the mechanism of action of anti-B-cell therapy for multiple sclerosis (MS) and the results of clinical trials of ocrelizumab, the first drug of this group, which has been approved for use in MS. Multicenter
Externí odkaz:
https://doaj.org/article/98d90177b6664c2b873515bd61666341
Publikováno v:
Neuroscience and Behavioral Physiology. 52:486-490
Active immunization of patients with autoimmune diseases is a current challenge. Vaccination of patients with multiple sclerosis (MS) has been shown not to be associated with increased risk of exacerbation. A personalized approach to immunization of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd4d07592d62d6724f77e184fe58b56e
https://doi.org/10.1007/s11055-022-01265-9
https://doi.org/10.1007/s11055-022-01265-9
Publikováno v:
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 121(7. Vyp. 2)
Immunization of the patients with autoimmune diseases is rising a lot of concerns. It was previously demonstrated that vaccination in MS patients was not associated with an increased risk of exacerbations. A personalized approach is needed to define
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5acdf0a12a30bcafcf1e7887fef0a65
https://pubmed.ncbi.nlm.nih.gov/34387445
https://pubmed.ncbi.nlm.nih.gov/34387445
Publikováno v:
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 121(7. Vyp. 2)
Recently anti-B-cell therapy has been increasingly integrated into the treatment of multiple sclerosis (MS). This review is devoted to ofatumumab, a new drug of this line. Ofatumumab, an all-human monoclonal antibody used to treat chronic leukemia, b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9418eec73b286e3df007465ee62f243d
https://pubmed.ncbi.nlm.nih.gov/34387444
https://pubmed.ncbi.nlm.nih.gov/34387444
Publikováno v:
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 121(7. Vyp. 2)
To study the effectiveness of non-drug methods of prevention and rehabilitation of patients with various variants of multiple sclerosis (MS) in outpatient settings.In a group of 35 patients with limited mobility with various variants of the course of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02edb2adebdc2f8f996b7b4c8fbe9d3a
https://pubmed.ncbi.nlm.nih.gov/34387446
https://pubmed.ncbi.nlm.nih.gov/34387446
Publikováno v:
Nevrologiâ, Nejropsihiatriâ, Psihosomatika, Vol 10, Iss 1, Pp 70-73 (2018)
The review presents the data characterizing the mechanism of action of anti-B-cell therapy for multiple sclerosis (MS) and the results of clinical trials of ocrelizumab, the first drug of this group, which has been approved for use in MS. Multicenter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8096afeedeb4773fdc8aa1d099490a6c
https://doi.org/10.14412/2074-2711-2018-1-70-73
https://doi.org/10.14412/2074-2711-2018-1-70-73
Publikováno v:
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 121:94
One of the leading symptoms in patients with multiple sclerosis (MS) is cognitive impairment. It often affects aspects of cognition such as learning ability, memory, processing speed, and attention. It has been proven that patients often complain of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ce7a4a58cf02098e5591255d959b7d5
https://doi.org/10.17116/jnevro202112107294
https://doi.org/10.17116/jnevro202112107294
Publikováno v:
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 120:73
Alemtuzumab (Lemtrada) is a recombinant humanized IgG1 kappa monoclonal antibody against cell surface glycoprotein CD 52. It is authorized in more than 65 countries worldwide including the Russian Federation. This is one of the most effective drugs f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::478a772d47de7a01f751ab24923eb825
https://doi.org/10.17116/jnevro202012007273
https://doi.org/10.17116/jnevro202012007273